Today, Novacyt has delivered a credible set of FY2025 results, beating market expectations on all three headline metrics, revenue, EBITDA loss, and cash, and demonstrating that the post-COVID restructuring phase is complete. With the cost base rightsized, manufacturing consolidated in Manchester, and a renewed product development pipeline beginning to bear commercial fruit, the Group is transitioning from a defensive consolidation story to an offensive growth one. The acquisition of Southern Cro ....
